Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Deals

Deals  ·  Weekly Digest - 20 September to 26 September 2025
Qurient and Synaffix partner to develop next-generation dual-payload ADCs

Weekly Digest – September 2025 Weekly Digest – September 2025 25 September 2025: Qurient and Synaffix partner to develop next-generation dual-payload ADCs Qurient entered into a licensing agreement with Synaffix (a Lonza subsidiary) to develop next-generation dual-payload ADCs, integrating Qurient’s […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 September to 26 September 2025
TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer

Weekly Digest – September 2025 Weekly Digest – September 2025 23 September 2025: TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer TegMine Therapeutics entered a strategic R&D collaboration with Boehringer Ingelheim to advance […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 September to 26 September 2025
Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration

Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration Mabwell Bioscience, Insilico Medicine, and ChemExpress formed a strategic collaboration to jointly develop […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 September to 26 September 2025
Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) Hengrui Pharma granted Glenmark exclusive rights (excluding major markets like China, US, […]

by Sandhya Ramalingam

Continue Reading


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id